Oct 2026· Cancer Chemotherapy and Pharmacology· Vol 96· 0 citations· 53 references
Medicine
TL;DR
This systematic review synthesized data from 13 studies evaluating the feasibility, histological fidelity, and clinical concordance of ovarian cancer patient-derived organoids to suggest PDOs represent a robust platform for functional drug screening within a clinically actionable 21-day window.
This review examines on-demand PDO generation through the selection of sample-processing methods, matrices, and platform architectures matched to specific treatment-response questions and compares conventional and engineered systems in terms of biological complexity, sample requirements, reported timelines, assay reado...
Prostate cancer ranks among the most prevalent male malignancies worldwide, with castration-resistant prostate cancer (CRPC) and drug resistance representing major clinical challenges. Conventional preclinical models fail to faithfully recapitulate tumor heterogeneity and the tumor microenvironment (TME). Patient-deriv...
Jing-Zhen Zhu, Sheng Wang, Fu-Rong Du et al.· Frontiers in Oncology· 0 citations
Ovarian cancer (OC) is the deadliest gynecological malignancy which continues to impose a significant challenge in the field of oncology research due to its rapid metastasis, inter and intra-tumor heterogeneity, and treatment resistance. Personalized medicine for OC is still under development where patient-derived orga...
A. Nikam, Gyamcho Tshering Bhutia, Sinjini Sarkar· Frontiers in Oncology· 0 citations
Patient‐derived organoids (PDOs) have emerged as an effective experimental platform for bridging the long‐standing gap between traditional in vitro cancer models and the biological complexity of actual tumors. These three‐dimensional cultures (3D), derived directly from patient tissues, preserve essential architectural...
Abdullah Jabri, Mohamed Alsharif, Abdulaziz Mhannayeh et al.· Cell Biochemistry and Functi...· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed at an advanced stage with limited treatment options. Patient-derived organoids (PDOs) can model tumors, identify determinants of therapeutic response, and support precision medicine. In the multi-institutional PASS-01 trial of metastatic PDAC, biopsies f...
A. Habowski, Fatim M. Kouassi, James A. Rouse et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.